AR045847A1 - Derivados del tiazol - Google Patents

Derivados del tiazol

Info

Publication number
AR045847A1
AR045847A1 ARP040103514A ARP040103514A AR045847A1 AR 045847 A1 AR045847 A1 AR 045847A1 AR P040103514 A ARP040103514 A AR P040103514A AR P040103514 A ARP040103514 A AR P040103514A AR 045847 A1 AR045847 A1 AR 045847A1
Authority
AR
Argentina
Prior art keywords
alkynyl
cycloalkyl
alkenyl
aryl
skin
Prior art date
Application number
ARP040103514A
Other languages
English (en)
Original Assignee
Avon Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avon Prod Inc filed Critical Avon Prod Inc
Publication of AR045847A1 publication Critical patent/AR045847A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los métodos son revelados para el mejoramiento de la apariencia de la piel mediante aplicación local de derivados de tiazol los cuales inhiben la formación de productos finales de la glucosilación avanzada, rompen los entrecruces asociados a los productos finales de la glucosilación avanzada e inhiben la función de la glucosa oxidasa. Composiciones cosméticas farmacéuticas que comprenden derivados de tiazol. Reivindicación 1: Una composición cosmética o farmacéutica para aplicación local que comprenda un compuesto inhibidor o de escisión de productos de la glucosilación avanzada de la fórmula (1), en donde R1, R2 y R3 son seleccionados independientemente de H; sustituidos o no sustituidos C1-10 alquil, alquenil, alquinil, aril, cicloalquil, y grupos heterocíclicos; NH2, NRaRb; SH; SR; CN; halógeno; OH; OR; SO3, SO3R; NO2; NO; C(=O)H; C(=O)R; C(=O)OH; C(=O)OR; (=O)NRaRb; donde R es seleccionado de H, sustituidos o no sustituidos C1-10 alquil, alquenil, alquinil, aril, cicloalquil, y grupos heterocíclicos; y donde Ra y Rb son seleccionados independientemente de H, sustituidos o no sustituidos C1-10 alquil, alquenil, alquinil, aril, cicloalquil, y grupos heterocíclicos; o una sal de ellos; y un vehículo farmacéutica o cosméticamente aceptable; en el que el citado compuesto este presente en una cantidad efectiva para el mejoramiento de la apariencia de la piel cuando sea aplicado localmente en la piel. Reivindicación 13: La composición de la reivindicación 1, en la que el citado compuesto es 2-amino-4,5-dimetiltiazol o una sal de ella.
ARP040103514A 2003-12-17 2004-09-28 Derivados del tiazol AR045847A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/738,412 US20050137239A1 (en) 2003-12-17 2003-12-17 Thiazole derivatives

Publications (1)

Publication Number Publication Date
AR045847A1 true AR045847A1 (es) 2005-11-16

Family

ID=34523171

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103514A AR045847A1 (es) 2003-12-17 2004-09-28 Derivados del tiazol

Country Status (10)

Country Link
US (1) US20050137239A1 (es)
EP (1) EP1543824A3 (es)
JP (1) JP2005179341A (es)
CN (1) CN1636563A (es)
AR (1) AR045847A1 (es)
AU (1) AU2004205185B2 (es)
BR (1) BRPI0404999A (es)
CA (1) CA2479432A1 (es)
MX (1) MXPA04012364A (es)
TW (1) TW200520783A (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2484342A1 (en) * 2005-07-29 2012-08-08 Shiseido Company, Limited Hair resiliency / body improver and hair cosmetic
GB0605949D0 (en) * 2006-03-24 2006-05-03 Quest Int Serv Bv Milk product for skin treatment
FR2918570B1 (fr) * 2007-07-09 2012-10-05 Engelhard Lyon DIGLYCATION DES AGEs.
DE102010012594A1 (de) * 2010-03-23 2011-09-29 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Thiazolderivaten
CA3054370A1 (en) * 2017-02-24 2018-08-30 Alzheon, Inc. Methods for treating neurodegenerative disorders
KR102076936B1 (ko) * 2019-08-12 2020-02-13 연세대학교 산학협력단 티아졸 또는 이의 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염 예방 또는 치료용 조성물
CN115697979A (zh) 2020-04-24 2023-02-03 拜耳公司 作为用于免疫激活的dgkzeta抑制剂的取代的氨基噻唑类

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321372A (en) * 1980-06-16 1982-03-23 Pfizer Inc. Antiulcer thiazol-2-ylcarbamoyl-carboxylic acids, esters and amides
CA2210684C (en) * 1995-01-18 2008-01-15 Alteon Inc. Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts
KR100766158B1 (ko) * 2000-01-19 2007-10-10 알테온 인크. 티아졸, 이미다졸 및 옥사졸 화합물, 및 단백질 노화와관련된 장애의 치료
MXPA02008276A (es) * 2000-02-23 2004-04-05 Alteon Inc Compuestos de tiazolio y tratamientos de trastornos asociados con el envejecimiento proteinico.
WO2001062247A1 (en) * 2000-02-25 2001-08-30 Avon Products, Inc. Topical compositions containing thiazolium compounds and methods of using same
EP1353676A4 (en) * 2000-12-29 2006-05-31 Alteon Inc METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS

Also Published As

Publication number Publication date
EP1543824A3 (en) 2005-09-14
MXPA04012364A (es) 2005-06-22
JP2005179341A (ja) 2005-07-07
CA2479432A1 (en) 2005-06-17
BRPI0404999A (pt) 2005-08-30
EP1543824A2 (en) 2005-06-22
AU2004205185B2 (en) 2007-11-22
CN1636563A (zh) 2005-07-13
US20050137239A1 (en) 2005-06-23
TW200520783A (en) 2005-07-01
AU2004205185A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
TW200420549A (en) Thiazole derivatives
ATE427941T1 (de) Thiazolderivate mit vap-1-hemmender wirkung
AR060545A1 (es) Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas
WO2006028269A3 (en) Thiazole derivatives having vap-1 ihibitory activity
BR9916566A (pt) Complexo de inibidor de ras-farnesiltransferase esulfobutiléter-7-ß-ciclodextrina ou2-hidroxipropil-ß-ciclodextrina e processo
BR0314071A (pt) Derivados de pró-droga de 1,3-diamino-2-hidroxipropano
ATE297203T1 (de) Antithrombotische mitteln
DE60141520D1 (de) 5-asa-derivate mit entzündungshemmender und antibiotischer wirkung und verfahren zur behandlung von krankheiten mit diesen derivaten
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
EA200800303A1 (ru) Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами
CO5170534A1 (es) Derivados de fenil propionamida como activadores de la glucoquinasa
RU2000102889A (ru) Применение производных колхинола в качестве средств, повреждающих сосуды
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BRPI0512252A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
EP1403255A4 (en) INHIBITORS OF RHO KINASE
BRPI0407695A (pt) compostos, processo para a preparação de um composto, composições farmacêuticas que compreendem o composto, utilização dos compostos e processo de tratamento para diabetes do tipo 2
EA200401615A1 (ru) ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
AR002751A1 (es) Antifungicos de tetrahidrofurano, composiciones farmaceuticas que los contienen y el uso de los compuestos para preparar composiciones farmaceuticas utiles para el tratamiento de infecciones fungicas
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
ECSP045420A (es) Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
AR045847A1 (es) Derivados del tiazol
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer

Legal Events

Date Code Title Description
FB Suspension of granting procedure